{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T17:13:47Z","timestamp":1779383627720,"version":"3.53.1"},"reference-count":95,"publisher":"BMJ","funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["ACF-2022-25-003"],"award-info":[{"award-number":["ACF-2022-25-003"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"accepted":{"date-parts":[[2026,4,23]]},"abstract":"<jats:p>Host inflammatory responses contribute substantially to infection-related morbidity, and in severe cases such as sepsis, acute respiratory distress syndrome (ARDS) and haemophagocytic lymphohistiocytosis, immune-mediated tissue injury may exceed the direct effects of pathogens themselves. Although traditional wisdom has considered immunosuppression risky when antimicrobial therapy is required, modern insights into immune biology reveal a more nuanced landscape in which targeted immunomodulators can attenuate harmful inflammation without broadly compromising host defence. This evolution is particularly relevant in paediatrics, influenced by developmental stage, distinct exposure history and patterns of host response. The COVID-19 pandemic catalysed wider acceptance of immunomodulation in infection management, including corticosteroids in children and highlighted safe use of agents such as baricitinib. Platform trials of the hyperinflammatory syndrome (paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2) also identified benefits of methylprednisolone and tocilizumab in select groups. For other paediatric infections, including dengue, influenza and Epstein-Barr virus, the evidence remains sparse, with emerging mechanistic and early-phase clinical studies exploring interleukin (IL)-1 blockade, corticosteroids, immunoglobulin and anticytokine biologics. In paediatric sepsis, immunophenotype-guided trials represent a major conceptual advance. Adaptive studies, such as TRIPS and GRACE-2, aim to tailor immunomodulation to hyperinflammation or immunoparalysis, though definitive efficacy data are awaited. Parallel efforts in ARDS explore statins, IL-6 blockade and cell-based therapies, but robust paediatric evidence is still lacking. Collectively, evolving insights and trial designs offer renewed opportunities to use targeted immunomodulation in the management of paediatric infection. Large-scale, collaborative paediatric research networks will be essential to translate these advances and better integrate infection research into everyday paediatric practice.<\/jats:p>","DOI":"10.1136\/archdischild-2025-330158","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:17:03Z","timestamp":1779380223000},"page":"archdischild-2025-330158","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Infection, inflammation and immune dysregulation: evolving perspectives on the host response"],"prefix":"10.1136","clinical-trial-number":[{"clinical-trial-number":"nct05267821","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03769844","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05266001","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05074420","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04898231","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05611710","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04381936","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02735707","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02735707","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04898231","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"isrctn81435672","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1845-2182","authenticated-orcid":false,"given":"Conor John","family":"O\u2019Donovan","sequence":"first","affiliation":[{"name":"School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK"},{"name":"Department of Paediatrics, Royal United Hospitals Bath, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8663-2401","authenticated-orcid":false,"given":"Athimalaipet V","family":"Ramanan","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK"},{"name":"Translational Health Sciences, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"2026052010201238000_archdischild-2025-330158v1.1","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S2352-4642(24)00141-X","article-title":"Susceptibility to childhood sepsis, contemporary management, and future directions","volume":"8","author":"Carter","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"key":"2026052010201238000_archdischild-2025-330158v1.2","doi-asserted-by":"publisher","DOI":"10.4049\/immunohorizons.2000104"},{"key":"2026052010201238000_archdischild-2025-330158v1.3","unstructured":"National Institute for Health and Care Excellent (NICE) . COVID-19 rapid guideline: managing COVID-19. 2021. Available: https:\/\/www.nice.org.uk\/guidance\/ng191"},{"key":"2026052010201238000_archdischild-2025-330158v1.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17023"},{"key":"2026052010201238000_archdischild-2025-330158v1.5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41392-021-00521-7","article-title":"Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Ma","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"2026052010201238000_archdischild-2025-330158v1.6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3345\/cep.2022.00458","article-title":"Therapeutics for the treatment of coronavirus disease 2019 in children and adolescents","volume":"65","author":"Choi","year":"2022","journal-title":"Clin Exp Pediatr"},{"key":"2026052010201238000_archdischild-2025-330158v1.7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/INF.0000000000003763","article-title":"Tocilizumab for Treatment of Children and Young Adults With Severe Acute COVID-19: Experience at a Quaternary-care Children\u2019s Hospital","volume":"42","author":"Teoh","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"2026052010201238000_archdischild-2025-330158v1.8","unstructured":"Roche Products Limited . RoActemra 20mg\/ml Concentrate for Solution for Infusion \u2013 Summary of Product Characteristics: Electronic Medicines Compendium. 2024. Available: https:\/\/www.medicines.org.uk\/emc\/product\/6673\/smpc"},{"key":"2026052010201238000_archdischild-2025-330158v1.9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","article-title":"Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial","volume":"10","author":"Ely","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026052010201238000_archdischild-2025-330158v1.10","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026052010201238000_archdischild-2025-330158v1.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-074373","article-title":"Colchicine for the treatment of patients with COVID-19: an updated systematic review and meta-analysis of randomised controlled trials","volume":"14","author":"Cheema","year":"2024","journal-title":"BMJ Open"},{"key":"2026052010201238000_archdischild-2025-330158v1.12","article-title":"Inhaled corticosteroids for the treatment of COVID-19","volume":"3","author":"Griesel","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2026052010201238000_archdischild-2025-330158v1.13","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jmii.2023.07.008","article-title":"Inhaled corticosteroid for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials","volume":"56","author":"Hsu","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"2026052010201238000_archdischild-2025-330158v1.14","doi-asserted-by":"crossref","first-page":"1131103","DOI":"10.3389\/fnut.2023.1131103","article-title":"Effect of vitamin D supplementation on COVID-19 patients: A systematic review and meta-analysis","volume":"10","author":"Zhang","year":"2023","journal-title":"Front Nutr"},{"key":"2026052010201238000_archdischild-2025-330158v1.15","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102013","article-title":"Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial","volume":"60","author":"Fran\u00e7ois","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026052010201238000_archdischild-2025-330158v1.16","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2213-2600(21)00177-6","article-title":"Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial","volume":"9","author":"Supady","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026052010201238000_archdischild-2025-330158v1.17","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S2352-4642(23)00316-4","article-title":"Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial","volume":"8","author":"Group","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"key":"2026052010201238000_archdischild-2025-330158v1.18","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S2352-4642(23)00020-2","article-title":"Methylprednisolone versus intravenous immunoglobulins in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): an open-label, multicentre, randomised trial","volume":"7","author":"Welzel","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"2026052010201238000_archdischild-2025-330158v1.19","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2023.101060","article-title":"Multisystem Inflammatory Syndrome therapies in children (MISTIC): A randomized trial","volume":"32","author":"Jain","year":"2023","journal-title":"Contemp Clin Trials Commun"},{"key":"2026052010201238000_archdischild-2025-330158v1.20","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S2352-4642(23)00341-3","article-title":"The RECOVERY trial of PIMS-TS: important lessons from the pandemic","volume":"8","author":"Son","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"key":"2026052010201238000_archdischild-2025-330158v1.21","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00244-24","article-title":"Dengue and severe dengue","volume":"38","author":"Kalimuddin","year":"2025","journal-title":"Clin Microbiol Rev"},{"key":"2026052010201238000_archdischild-2025-330158v1.22","doi-asserted-by":"crossref","unstructured":"Halstead SB . Pathogenesis: Risk Factors Prior to Infection. Dengue 2008;219\u201356. doi:10.1142\/9781848162297_0007","DOI":"10.1142\/9781848162297_0007"},{"key":"2026052010201238000_archdischild-2025-330158v1.23","article-title":"Dengue haemorrhagic fever or dengue shock syndrome in children","volume":"2009","author":"Alejandria","year":"2009","journal-title":"BMJ Clin Evid"},{"key":"2026052010201238000_archdischild-2025-330158v1.24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1600999","article-title":"Dysregulated immune cell responses in severe dengue pathogenesis","volume":"16","author":"Yoo","year":"2025","journal-title":"Front Immunol"},{"key":"2026052010201238000_archdischild-2025-330158v1.25","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2025-329078"},{"key":"2026052010201238000_archdischild-2025-330158v1.26","doi-asserted-by":"crossref","DOI":"10.12688\/wellcomeopenres.21017.1","article-title":"Anakinra for dengue patients with hyperinflammation: protocol for a randomized double-blind placebo-controlled trial","volume":"9","author":"Huyen","year":"2024","journal-title":"Wellcome Open Res"},{"key":"2026052010201238000_archdischild-2025-330158v1.27","article-title":"Corticosteroids as adjunctive therapy in the treatment of influenza","volume":"2","author":"Lansbury","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2026052010201238000_archdischild-2025-330158v1.28","unstructured":"World Health Organization . Guidelines for the clinical management of severe illness from influenza virus infections. Geneva, 2021."},{"key":"2026052010201238000_archdischild-2025-330158v1.29","unstructured":"World Health Organization . Clinical practice guidelines for influenza. Geneva, 2024."},{"key":"2026052010201238000_archdischild-2025-330158v1.30","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1093\/infdis\/jiaf276","article-title":"Platform Trials to Assess Therapeutics in Patients Hospitalized With Influenza","volume":"232","author":"Waite","year":"2025","journal-title":"J Infect Dis"},{"key":"2026052010201238000_archdischild-2025-330158v1.31","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.7861\/fhj.2021-0083","article-title":"Making trials part of good clinical care: lessons from the RECOVERY trial","volume":"8","author":"Pessoa-Amorim","year":"2021","journal-title":"Future Healthc J"},{"key":"2026052010201238000_archdischild-2025-330158v1.32","doi-asserted-by":"crossref","first-page":"100901","DOI":"10.1016\/j.jbior.2022.100901","article-title":"Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial","volume":"86","author":"Peto","year":"2022","journal-title":"Adv Biol Regul"},{"key":"2026052010201238000_archdischild-2025-330158v1.33","unstructured":"RECOVERY Trial . Dexamethasone for influenza - intervention information sheet. 2025."},{"key":"2026052010201238000_archdischild-2025-330158v1.34","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1093\/infdis\/jiaf328","article-title":"Host Immunomodulatory Interventions in Severe Influenza","volume":"232","author":"Hui","year":"2025","journal-title":"J Infect Dis"},{"key":"2026052010201238000_archdischild-2025-330158v1.35","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2015.74"},{"key":"2026052010201238000_archdischild-2025-330158v1.36","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3390\/ijms24010678","article-title":"Alloferon and Zanamivir Show Effective Antiviral Activity against Influenza A Virus (H1N1) Infection In Vitro and In Vivo","volume":"24","author":"Lee","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026052010201238000_archdischild-2025-330158v1.37","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41586-024-07265-8","article-title":"Necroptosis blockade prevents lung injury in severe influenza","volume":"628","author":"Gautam","year":"2024","journal-title":"Nature New Biol"},{"key":"2026052010201238000_archdischild-2025-330158v1.38","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12386"},{"key":"2026052010201238000_archdischild-2025-330158v1.39","doi-asserted-by":"publisher","DOI":"10.46747\/cfp.6902101"},{"key":"2026052010201238000_archdischild-2025-330158v1.40","doi-asserted-by":"publisher","DOI":"10.1097\/00008480-200006000-00016"},{"key":"2026052010201238000_archdischild-2025-330158v1.41","article-title":"Steroids for symptom control in infectious mononucleosis","volume":"2015","author":"Rezk","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2026052010201238000_archdischild-2025-330158v1.42","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/hematology.2024000583","article-title":"EBV and post-transplant lymphoproliferative disorder: a complex relationship","volume":"2024","author":"El-Mallawany","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2026052010201238000_archdischild-2025-330158v1.43","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11020322","article-title":"Sirolimus-Based Immunosuppression Is Associated with Decreased Incidence of Post-Transplant Lymphoproliferative Disorder after Heart Transplantation: A Double-Center Study","volume":"11","author":"Asleh","year":"2022","journal-title":"J Clin Med"},{"key":"2026052010201238000_archdischild-2025-330158v1.44","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00649-6"},{"key":"2026052010201238000_archdischild-2025-330158v1.45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjh.17638","article-title":"Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes","volume":"196","author":"El-Mallawany","year":"2022","journal-title":"Br J Haematol"},{"key":"2026052010201238000_archdischild-2025-330158v1.46","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181f84a52"},{"key":"2026052010201238000_archdischild-2025-330158v1.47","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/infdis\/jiaf556","article-title":"Risk- and Response-Adapted Treatment in Pediatric Epstein-Barr Virus\u2013Associated Hemophagocytic Lymphohistiocytosis","volume":"233","author":"Miao","year":"2026","journal-title":"J Infect Dis"},{"key":"2026052010201238000_archdischild-2025-330158v1.48","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039"},{"key":"2026052010201238000_archdischild-2025-330158v1.49","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1002\/art.42636","article-title":"The 2022 EULAR\/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis\/Macrophage Activation Syndrome (HLH\/MAS)","volume":"75","author":"Shakoory","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026052010201238000_archdischild-2025-330158v1.50","doi-asserted-by":"crossref","first-page":"100060","DOI":"10.1016\/j.clinpr.2020.100060","article-title":"Epstein-Barr virus associated haemophagocytic lymphohistiocytosis treated with anakinra and rituximab: A case report","volume":"9","author":"McCann","year":"2021","journal-title":"Clinical Infection in Practice"},{"key":"2026052010201238000_archdischild-2025-330158v1.51","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018894618"},{"key":"2026052010201238000_archdischild-2025-330158v1.52","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000039880","article-title":"Emapalumab as a therapeutic intervention for Epstein\u2013Barr virus-associated hemophagocytic lymphohistiocytosis: A case series","volume":"103","author":"Wang","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"2026052010201238000_archdischild-2025-330158v1.53","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S2213-2600(23)00468-X","article-title":"Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies","volume":"12","author":"Shankar-Hari","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026052010201238000_archdischild-2025-330158v1.54","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1038\/s41591-025-03956-5","article-title":"A consensus immune dysregulation framework for sepsis and critical illnesses","volume":"31","author":"Moore","year":"2025","journal-title":"Nat Med"},{"key":"2026052010201238000_archdischild-2025-330158v1.55","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1038\/s41591-025-03964-5","article-title":"A consensus blood transcriptomic framework for sepsis","volume":"31","author":"Scicluna","year":"2025","journal-title":"Nat Med"},{"key":"2026052010201238000_archdischild-2025-330158v1.56","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03933-y"},{"key":"2026052010201238000_archdischild-2025-330158v1.57","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-023-04762-6"},{"key":"2026052010201238000_archdischild-2025-330158v1.58","doi-asserted-by":"crossref","DOI":"10.1093\/burnst\/tkaf001","article-title":"Recent advances of precision immunotherapy in sepsis","volume":"13","author":"Arapis","year":"2025","journal-title":"Burns Trauma"},{"key":"2026052010201238000_archdischild-2025-330158v1.59","article-title":"Corticosteroids for treating sepsis in children and adults","volume":"6","author":"Annane","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"2026052010201238000_archdischild-2025-330158v1.60","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14121155","article-title":"Corticosteroids in Pediatric Septic Shock: A Narrative Review","volume":"14","author":"Rulli","year":"2024","journal-title":"J Pers Med"},{"key":"2026052010201238000_archdischild-2025-330158v1.61","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/INF.0000000000004551","article-title":"Corticosteroids for Managing Pediatric Sepsis and Septic Shock: A Systematic Review and Meta-analysis","volume":"44","author":"Deng","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"2026052010201238000_archdischild-2025-330158v1.62","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14092983","article-title":"Immunomodulation in Pediatric Sepsis: A Narrative Review","volume":"14","author":"Bottari","year":"2025","journal-title":"J Clin Med"},{"key":"2026052010201238000_archdischild-2025-330158v1.63","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-024-04964-6","article-title":"Towards personalized medicine: a scoping review of immunotherapy in sepsis","volume":"28","author":"Slim","year":"2024","journal-title":"Crit Care"},{"key":"2026052010201238000_archdischild-2025-330158v1.64","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-023-04592-8","article-title":"Efficacy of IVIG therapy for patients with sepsis: a systematic review and meta-analysis","volume":"21","author":"Pan","year":"2023","journal-title":"J Transl Med"},{"key":"2026052010201238000_archdischild-2025-330158v1.65","doi-asserted-by":"publisher","DOI":"10.1007\/S00134-021-06506-Y"},{"key":"2026052010201238000_archdischild-2025-330158v1.66","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/PCC.0000000000003927","article-title":"Surviving Sepsis Campaign International Guidelines for the Management of Sepsis and Septic Shock in Children 2026","volume":"27","author":"Weiss","year":"2026","journal-title":"Pediatr Crit Care Med"},{"key":"2026052010201238000_archdischild-2025-330158v1.67","unstructured":"NHS England . Clinical commissioning policy for the use of therapeutic immunoglobulin (Ig) England (2025). 2025."},{"key":"2026052010201238000_archdischild-2025-330158v1.68","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1239014","article-title":"Clinical efficacy of IgM-enriched immunoglobulin as adjunctive therapy in neonatal and pediatric sepsis: a systematic review and meta-analysis","volume":"11","author":"Dinleyici","year":"2023","journal-title":"Front Pediatr"},{"key":"2026052010201238000_archdischild-2025-330158v1.69","doi-asserted-by":"crossref","DOI":"10.1186\/s13613-020-00740-1","article-title":"Best-practice IgM- and IgA-enriched immunoglobulin use in patients with sepsis","volume":"10","author":"Nierhaus","year":"2020","journal-title":"Ann Intensive Care"},{"key":"2026052010201238000_archdischild-2025-330158v1.70","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0000000000003332"},{"key":"2026052010201238000_archdischild-2025-330158v1.71","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-067251","article-title":"ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol","volume":"12","author":"Kotsaki","year":"2022","journal-title":"BMJ Open"},{"key":"2026052010201238000_archdischild-2025-330158v1.72","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2022.100817","article-title":"Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial","volume":"3","author":"Leventogiannis","year":"2022","journal-title":"Cell Rep Med"},{"key":"2026052010201238000_archdischild-2025-330158v1.73","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDra2200118","article-title":"Immune Modulation in Sepsis, ARDS, and Covid-19 - The Road Traveled and the Road Ahead","volume":"1","author":"Leligdowicz","year":"2022","journal-title":"NEJM Evid"},{"key":"2026052010201238000_archdischild-2025-330158v1.74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-025-02127-9","article-title":"Advances in acute respiratory distress syndrome: focusing on heterogeneity, pathophysiology, and therapeutic strategies","volume":"10","author":"Ma","year":"2025","journal-title":"Sig Transduct Target Ther"},{"key":"2026052010201238000_archdischild-2025-330158v1.75","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1080\/14656566.2024.2374461","article-title":"An update on the pharmacological management of acute respiratory distress syndrome","volume":"25","author":"Battaglini","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"2026052010201238000_archdischild-2025-330158v1.76","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-021-06394-2"},{"key":"2026052010201238000_archdischild-2025-330158v1.77","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","article-title":"Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial","volume":"8","author":"Villar","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026052010201238000_archdischild-2025-330158v1.78","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/PCC.0000000000000349","article-title":"Double-blind, placebo-controlled pilot randomized trial of methylprednisolone infusion in pediatric acute respiratory distress syndrome","volume":"16","author":"Drago","year":"2015","journal-title":"Pediatr Crit Care Med"},{"key":"2026052010201238000_archdischild-2025-330158v1.79","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-015-3953-4"},{"key":"2026052010201238000_archdischild-2025-330158v1.80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225737","article-title":"Improved oxygenation following methylprednisolone therapy and survival in paediatric acute respiratory distress syndrome","volume":"14","author":"Mitting","year":"2019","journal-title":"PLoS One"},{"key":"2026052010201238000_archdischild-2025-330158v1.81","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S2213-2600(13)70259-5","article-title":"The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study","volume":"2","author":"Bellingan","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026052010201238000_archdischild-2025-330158v1.82","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.22525"},{"key":"2026052010201238000_archdischild-2025-330158v1.83","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-023-04394-w","article-title":"Interleukin-6 inhibitors in non-COVID-19 ARDS: analyzing the past to step into the post-COVID-19 era","volume":"27","author":"Gandini","year":"2023","journal-title":"Crit Care"},{"key":"2026052010201238000_archdischild-2025-330158v1.84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309995"},{"key":"2026052010201238000_archdischild-2025-330158v1.85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403285"},{"key":"2026052010201238000_archdischild-2025-330158v1.86","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11185454","article-title":"Systematic Review and Meta-Analysis of Statin Use and Mortality, Intensive Care Unit Admission and Requirement for Mechanical Ventilation in COVID-19 Patients","volume":"11","author":"Lao","year":"2022","journal-title":"J Clin Med"},{"key":"2026052010201238000_archdischild-2025-330158v1.87","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-2600(18)30177-2","article-title":"Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial","volume":"6","author":"Calfee","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026052010201238000_archdischild-2025-330158v1.88","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12931-023-02346-0","article-title":"Inhaled prostacyclin therapy in the acute respiratory distress syndrome: a randomized controlled multicenter trial","volume":"24","author":"Haeberle","year":"2023","journal-title":"Respir Res"},{"key":"2026052010201238000_archdischild-2025-330158v1.89","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202201-0157OC"},{"key":"2026052010201238000_archdischild-2025-330158v1.90","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-022-04287-4"},{"key":"2026052010201238000_archdischild-2025-330158v1.91","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/17476348.2025.2583354","article-title":"Mesenchymal stromal cell-derived extracellular vesicles as a next-generation therapy for ARDS: mechanisms, advances, and future directions","volume":"20","author":"Costa-Ferro","year":"2026","journal-title":"Expert Rev Respir Med"},{"key":"2026052010201238000_archdischild-2025-330158v1.92","doi-asserted-by":"publisher","DOI":"10.1136\/fetalneonatal-2011-301470"},{"key":"2026052010201238000_archdischild-2025-330158v1.93","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60071-4"},{"key":"2026052010201238000_archdischild-2025-330158v1.94","article-title":"G-CSF and GM-CSF for treating or preventing neonatal infections","volume":"2003","author":"Carr","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"2026052010201238000_archdischild-2025-330158v1.95","doi-asserted-by":"crossref","DOI":"10.1186\/s13052-025-01863-6","article-title":"The effect of GM-CSF and predictors of treatment outcome in pediatric septic shock patients","volume":"51","author":"Yu","year":"2025","journal-title":"Ital J Pediatr"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2025-330158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:17:13Z","timestamp":1779380233000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2025-330158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":95,"alternative-id":["10.1136\/archdischild-2025-330158"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2025-330158","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]}}}